Skip to main
OKUR
OKUR logo

OKUR Stock Forecast & Price Target

OKUR Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OnKure Therapeutics Inc demonstrated a narrower-than-expected net loss of $1.14 per share in 2Q25, indicating better financial performance relative to prior estimates. The company's lead product candidate, OKI-219, exhibited a favorable safety profile, being well-tolerated across all dose levels without any severe adverse events, thus underscoring the potential for successful future development. These factors collectively suggest a strong foundation for the company's growth and advancement in precision cancer therapies, which are targeting underserved treatment areas.

Bears say

OnKure Therapeutics is projecting a significant annual net loss of $4.56 per share for the year 2025, an improvement from its previous estimate of $4.75 per share, yet still indicative of the company's ongoing financial struggles. The company faces multiple risks, including potential negative clinical results associated with its lead asset, OKI-219, and delays in advancing its pipeline candidates, which could further complicate its path to regulatory approvals. Additionally, there are concerns regarding competitive pressures from other therapies in the market that could hinder OnKure's growth prospects, along with the risk of long-term shareholder dilution.

OKUR has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OnKure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OnKure Therapeutics Inc (OKUR) Forecast

Analysts have given OKUR a Strong Buy based on their latest research and market trends.

According to 3 analysts, OKUR has a Strong Buy consensus rating as of Dec 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OnKure Therapeutics Inc (OKUR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.